1. Scrip
  2. >>Business

AbbVie: Rinvoq And Skyrizi Will Bridge US Humira Sales Erosion Through 2025

 
• By Joseph Haas

Continuing its longstanding effort to assure investors about growth past Humira’s US patent expiry in 2023, the pharma outlined label-expansion and market share plans for its two newer immunology drugs.

R&D management
AbbVie is undertaking numerous R&D efforts to replace soon-diminishing Humira revenue

AbbVie Inc. believes Rinvoq and Skyrizi combined can generate $15bn in annual sales by 2025, completely offsetting the expected US sales erosion of Humira once biosimilars enter the market, expected in early 2023. The Chicago pharma overviewed its post-Humira ambitions in immunology during an investor presentation on 14 December.

Skyrizi (risankizumab), an interleukin-23 inhibiting antibody therapy launched initially for psoriasis in 2019, and Rinvoq (upadacitinib), an oral JAK1 inhibitor approved for moderate-to-severe rheumatoid arthritis in August 2019, have been cited as key components of AbbVie’s post-Humira (adalimumab) plan for years now, but the $15bn sales prediction in 2025 is above analysts’ consensus estimates for the two drugs, even as the launches appear off to a strong start

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.